PriceTargets.com logo

Indiva - NDVA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.15
  • Forecasted Upside: 150.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$0.06 As of 04/17/2024 06:33 PM ET
▼ -0.005 (-7.69%)

This chart shows the closing price for NDVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indiva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NDVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NDVA

Analyst Price Target is C$0.15
▲ +150.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Indiva in the last 3 months. The average price target is C$0.15, with a high forecast of C$0.15 and a low forecast of C$0.15. The average price target represents a 150.00% upside from the last price of C$0.06.

This chart shows the closing price for NDVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Indiva. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/5/2024Echelon Wealth PartnersBoost TargetSpeculative BuyC$0.13 ➝ C$0.15
11/22/2023Echelon Wealth PartnersUpgradeHold ➝ Speculative BuyC$0.10 ➝ C$0.13
4/27/2022Raymond JamesSet TargetOutperformC$0.60
4/21/2022Raymond JamesLower TargetOutperformC$1.25 ➝ C$0.60
11/17/2021Raymond JamesSet TargetOutperformC$1.25
10/15/2021Raymond JamesDowngradeStrong-Buy ➝ OutperformC$1.75 ➝ C$1.25
9/7/2021Raymond JamesSet TargetStrong-BuyC$1.75
12/22/2020Fundamental ResearchBoost TargetBuyC$0.55 ➝ C$0.63
12/8/2020Fundamental ResearchDropped CoverageTop Pick ➝ BuyC$0.55 ➝ C$0.63
9/22/2020Fundamental ResearchLower TargetTop Pick ➝ BuyC$0.59 ➝ C$0.55
6/16/2020Fundamental ResearchSet TargetTop Pick ➝ BuyC$0.62
5/21/2020Fundamental ResearchBoost TargetTop Pick ➝ Top PickC$0.40 ➝ C$0.62
4/8/2020Fundamental ResearchInitiated CoverageTop PickC$0.40
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Indiva logo
Indiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.
Read More

Today's Range

Now: C$0.06
Low: C$0.06
High: C$0.07

50 Day Range

MA: C$0.08
Low: C$0.06
High: C$0.10

52 Week Range

Now: C$0.06
Low: C$0.02
High: C$0.13

Volume

92,000 shs

Average Volume

102,702 shs

Market Capitalization

C$11.72 million

P/E Ratio

N/A

Dividend Yield

4.04%

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Indiva?

The following Wall Street analysts have issued research reports on Indiva in the last year: Echelon Wealth Partners.
View the latest analyst ratings for NDVA.

What is the current price target for Indiva?

1 Wall Street analysts have set twelve-month price targets for Indiva in the last year. Their average twelve-month price target is C$0.15, suggesting a possible upside of 150.0%. Echelon Wealth Partners has the highest price target set, predicting NDVA will reach C$0.15 in the next twelve months. Echelon Wealth Partners has the lowest price target set, forecasting a price of C$0.15 for Indiva in the next year.
View the latest price targets for NDVA.

What is the current consensus analyst rating for Indiva?

Indiva currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NDVA will outperform the market and that investors should add to their positions of Indiva.
View the latest ratings for NDVA.

What other companies compete with Indiva?

Other companies that are similar to Indiva include Medicure, Flowr, Valeo Pharma, Willow Biosciences and Nuvo Pharmaceuticals. Learn More about companies similar to Indiva.

How do I contact Indiva's investor relations team?

Indiva's physical mailing address is 333 Preston Street, Suite 710, Ottawa, ON K1S 5N4, Canada. The company's listed phone number is 888-649-6686. The official website for Indiva is indiva.ca. Learn More about contacing Indiva investor relations.